{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T13:24:03Z","timestamp":1775136243490,"version":"3.50.1"},"reference-count":73,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Breast cancer is a complex disease whose molecular mechanisms are not completely understood. Developing target therapies is a promising approach. Therefore, understanding the biological behavior of the tumor is a challenge. Tissue biopsy in the metastatic setting remains the standard method for diagnosis. Nevertheless, it has been associated with some disadvantages: It is an invasive procedure, it may not represent tumor heterogeneity, and it does not allow for treatment efficacy to be assessed or early recurrences to be detected. Analysis of circulating tumor DNA (ctDNA) may help to overcome this as it is a non-invasive method of monitoring the disease. In early-stage disease, it can detect early recurrences and monitor tumors\u2019 genomic profiles, identifying the emergence of new genetic alterations which can be related to tumor-acquired resistance. In the metastatic setting, the analysis of ctDNA may also allow for the anticipation of clinical and radiological progression of the disease, selection of targeted therapies, and for a photogram of tumor heterogeneity to be provided. It may also detect disease progression earlier in locally advanced tumors submitted to neoadjuvant treatment, and identify minimal residual disease. ctDNA analysis may guide clinical decision-making in different scenarios, in a precision medicine era, once it acts as a repository of genetic tumor material, allowing for a comprehensive mutation profiling analysis. In this review, we focused on recent advances towards the implementation of ctDNA in a clinical routine for breast cancer.<\/jats:p>","DOI":"10.3390\/cancers12123797","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T09:21:15Z","timestamp":1608110475000},"page":"3797","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Utility of Circulating Tumor DNA in Different Clinical Scenarios of Breast Cancer"],"prefix":"10.3390","volume":"12","author":[{"given":"Alexandra","family":"Mesquita","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Hospital Pedro Hispano, Unidade Local Sa\u00fade Matosinhos, 4464-513 Senhora da Hora, Portugal"},{"name":"Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7132-4094","authenticated-orcid":false,"given":"Jos\u00e9 Lu\u00eds","family":"Costa","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-6946","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"vi7","DOI":"10.1093\/annonc\/mdt284","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"6","author":"Senkus","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: A promising biomarker in the liquid biopsy of cancer","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","article-title":"Circulating tumor DNA as a liquid biopsy for cancer","volume":"61","author":"Heitzer","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.molonc.2015.12.001","article-title":"Cell free circulating tumor DNA as a liquid biopsy in breast cancer","volume":"10","author":"Arruda","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1093\/annonc\/mdx288","article-title":"Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions","volume":"28","author":"Reguart","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_8","first-page":"1044","article-title":"Circulating tumor DNA in colorectal cancer: Opportunities and challenges","volume":"12","author":"Bi","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/emboj.2013.19","article-title":"A new genome-driven integrated classification of breast cancer and its implications","volume":"32","author":"Dawson","year":"2013","journal-title":"EMBO J."},{"key":"ref_11","first-page":"241","article-title":"Les acides nucl\u00e9iques du plasma sanguin chez l\u2019homme","volume":"142","author":"Mandel","year":"1948","journal-title":"CR Seances Soc. Biol. Fil."},{"key":"ref_12","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/cge.13514","article-title":"Liquid biopsy in breast cancer: A comprehensive review","volume":"95","author":"Alimirzaie","year":"2019","journal-title":"Clin. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/gm474","article-title":"Circulating tumor cells versus tumor-derived cell-free DNA: Rivals or partners in cancer care in the era of single-cell analysis?","volume":"5","author":"Kidess","year":"2013","journal-title":"Genom. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: Genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2019.12.023","article-title":"Induction of apoptosis increases sensitivity to detect cancer mutations in plasma","volume":"127","author":"Marques","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ijc.20240","article-title":"Microsatellite analysis of serum DNA in patients with head and neck cancer","volume":"111","author":"Eisenberger","year":"2004","journal-title":"Int. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"48","DOI":"10.5808\/GI.2017.15.1.48","article-title":"Circulating tumor DNA in a breast cancer patient\u2019s plasma represents driver alterations in the tumor tissue","volume":"15","author":"Lee","year":"2017","journal-title":"Genomics Inform."},{"key":"ref_20","first-page":"235","article-title":"\u201cLiquid biopsy\u201d\u2014ctDNA detection with great potential and challenges","volume":"3","author":"Ma","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Keller, L., Belloum, Y., Wikman, H., and Pantel, K. (2020). Clinical relevance of blood-based ctDNA analysis: Mutation detection and beyond. Br. J. Cancer.","DOI":"10.1038\/s41416-020-01047-5"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2017.05.014","article-title":"Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis","volume":"110","author":"Sands","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid derived circulating tumor DNA better represents the genomic alterations of brain tumors than plasma","volume":"6","author":"Mayor","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_24","first-page":"77","article-title":"Saliva liquid biopsy for point-of-care applications","volume":"5","author":"Aro","year":"2017","journal-title":"Front. Public Heal."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kaisaki, P.J., Cutts, A., Popitsch, N., Herrero, C.C., Pentony, M.M., Wilson, G., Page, S., Kaur, K., Vavoulis, D., and Henderson, S. (2016). Targeted next-generation sequencing of plasma DNA from cancer patients: Factors influencing consistency with tumor DNA and prospective investigation of its utility for diagnosis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0162809"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-17-0061","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus circulating tumor DNA in breast cancer","volume":"16","author":"Chae","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.pharmthera.2015.11.007","article-title":"Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies","volume":"157","author":"Esposito","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40246-019-0220-8","article-title":"Next-generation sequencing in liquid biopsy: Cancer screening and early detection","volume":"13","author":"Chen","year":"2019","journal-title":"Hum. Genomics"},{"key":"ref_29","first-page":"2057","article-title":"Systematic dissection of biases in whole-exome and whole-genome sequencing reveals major determinants of coding sequence coverage","volume":"10","author":"Barbitoff","year":"2020","journal-title":"Nat. Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lim, M., Kim, C.J., Sunkara, V., Kim, M.-H., and Cho, Y.-K. (2018). Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA). Micromachines, 9.","DOI":"10.3390\/mi9030100"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Spence, T., Perera, S., Weiss, J., Grenier, S., Ranich, L., Shepherd, F., and Stockley, T.L. (2020). Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer. J. Clin. Pathol., 1\u20137.","DOI":"10.1136\/jclinpath-2020-206668"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"455","DOI":"10.21037\/tlcr.2016.10.07","article-title":"Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring","volume":"5","author":"Romero","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","article-title":"Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers","volume":"25","author":"Parikh","year":"2019","journal-title":"Nat. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrclinonc.2013.80","article-title":"Circulating tumor cells and cell-free DNA as tools for managing breast cancer","volume":"10","author":"Cortes","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"Diaz","year":"2012","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"106901","DOI":"10.18632\/oncotarget.22456","article-title":"Detection of somatic variants and EGFR mutations in cell-free DNA from non-small cell lung cancer patients by ultra-deep sequencing using the ion ampliseq cancer hotspot panel and droplet digital polymerase chain reaction","volume":"8","author":"Sung","year":"2017","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.tranon.2017.07.004","article-title":"Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients","volume":"10","author":"Takeshita","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Woodhouse, R., Li, M., Hughes, J., Delfosse, D., Skoletsky, J., Ma, P., Meng, W., Dewal, N., Milbury, C., and Clark, T. (2020). Clinical and analytical validation of FoundationOne\u00aeLiquid CDx assay a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237802"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1158\/1078-0432.CCR-19-0624","article-title":"Clinical utility of comprehensive cell free DNAanalyses to identify genomic biomarkers I patients with newly diagnosed metastatic non-small cell lung cancers","volume":"25","author":"Leighl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_40","unstructured":"US. Food and Drug Administration (FDA) (2020, October 10). Available online: www.fda.gov."},{"key":"ref_41","first-page":"111","article-title":"Prostate tissue and serum markers","volume":"4","author":"Mazzucchelli","year":"2000","journal-title":"Adv. Clin. Pathol. Off. J. Adriat. Soc. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1158\/1078-0432.CCR-18-3663","article-title":"Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence","volume":"25","author":"Coombes","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"31985","DOI":"10.1038\/srep31985","article-title":"Circulating tumor DNA detection in early-stage non-small cell lung cancer patients by targeted sequencing","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10549-010-0747-9","article-title":"Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer","volume":"120","author":"Board","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/1078-0432.CCR-13-2933","article-title":"Detection of cancer DNA in plasma of early stage breast cancer patients","volume":"20","author":"Beaver","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer","volume":"5","author":"Chopra","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1200\/JCO.2010.32.9615","article-title":"Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer","volume":"29","author":"Kim","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_51","first-page":"6","article-title":"On behalf of the CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.cca.2010.08.039","article-title":"CA 15-3: Uses and limitation as a biomarker for breast cancer","volume":"411","author":"Duffy","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/1759-7714.12793","article-title":"Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer","volume":"9","author":"Lee","year":"2018","journal-title":"Thorac. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer","volume":"368","author":"Dawson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1373\/clinchem.2015.238717","article-title":"Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer","volume":"61","author":"Guttery","year":"2015","journal-title":"Clin. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ERS1 mutations and treatment of estrogen receptor positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"522","DOI":"10.4103\/0366-6999.200542","article-title":"Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer","volume":"130","author":"Ye","year":"2017","journal-title":"Chin. Med. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.breast.2019.12.010","article-title":"Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer","volume":"49","author":"Guan","year":"2020","journal-title":"Breast"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","article-title":"Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials","volume":"13","author":"Fritsch","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Ciruelos","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"GS3-08","DOI":"10.1158\/1538-7445.SABCS18-GS3-08","article-title":"Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial","volume":"79","author":"Juric","year":"2019","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"PD1-13","DOI":"10.1158\/1538-7445.SABCS17-PD1-13","article-title":"Abstract PD1-13: Somatic BRCA mutation detection by circulating tumor DNA analysis in patients with metastatic breast cancer: Incidence and association with tumor genotyping results, germline BRCA mutation status, and clinical outcomes","volume":"78","author":"Vidula","year":"2018","journal-title":"Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1 mutations and acquired resistance to CDK 4\/6 inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/annonc\/mdy017","article-title":"Circulating tumour DNA analyses reveal novel resistance mechanisms to CDK inhibition in metastatic breast cancer","volume":"28","author":"Abbosh","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): A multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_69","first-page":"S1","article-title":"Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC)","volume":"72","author":"Cortazar","year":"2012","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-18-2521","article-title":"Circulating tumor DNA in HER2-amplified breast cancer translational research substudy of the NeoALTTO phase III trial","volume":"25","author":"Silva","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"eaax7392","DOI":"10.1126\/scitranslmed.aax7392","article-title":"Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer","volume":"11","author":"McDonald","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1373\/clinchem.2016.262337","article-title":"Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer","volume":"63","author":"Riva","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3797\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:45:50Z","timestamp":1760179550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/12\/3797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,16]]},"references-count":73,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["cancers12123797"],"URL":"https:\/\/doi.org\/10.3390\/cancers12123797","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,16]]}}}